EYPT - EyePoint pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

212.1M

Cash

299.3M

Avg Qtr Burn

-3.115M

Short % of Float

29.40%

Insider Ownership

1.44%

Institutional Own.

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
YUTIQ Details Chronic non-infectious uveitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DEXYCU Details Post-operative inflammation	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DURAVYU™ (vorolanib intravitreal insert) (EYP-1901) Details Wet age-related macular degeneration , Macular degeneration	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DURAVYU (EYP-1901) Details Diabetic macular edema	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EYP-1901 Details Non-proliferative diabetic retinopathy	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.